BAXTER INTERNATIONAL INC. Baxter International Inc. Stock
Equities
BAX
US0718131099
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 35.17 USD | -0.73% |
|
-2.17% | -9.03% |
| May. 13 | Baxter International's Clinolipid Injection Approved for Expanded Use in US | MT |
| May. 10 | TD Cowen Downgrades Baxter International to Hold From Buy, Price Target is $40 | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 15.11B | Sales 2025 * | 15.66B | Capitalization | 17.92B |
|---|---|---|---|---|---|
| Net income 2024 * | 703M | Net income 2025 * | 950M | EV / Sales 2024 * | 1.83 x |
| Net Debt 2024 * | 9.7B | Net Debt 2025 * | 8.8B | EV / Sales 2025 * | 1.71 x |
| P/E ratio 2024 * |
19.1
x | P/E ratio 2025 * |
15.7
x | Employees | 60,000 |
| Yield 2024 * |
3.39% | Yield 2025 * |
3.52% | Free-Float | 74.06% |
More Fundamentals
* Assessed data
More news
Latest transcript on Baxter International Inc.
More recommendations
More press releases
| 1 day | -0.73% | ||
| 1 week | -2.17% | ||
| Current month | -12.88% | ||
| 1 month | -11.12% | ||
| 3 months | -14.68% | ||
| 6 months | -0.79% | ||
| Current year | -9.03% |
1 week
34.94
36.08
1 month
34.9441.18
Current year
34.9444.01
1 year
31.0150.21
3 years
31.0189.70
5 years
31.0195.19
10 years
31.0195.19
| Managers | Title | Age | Since |
|---|---|---|---|
Joe Almeida
CEO | Chief Executive Officer | 61 | 15-09-30 |
Joel Grade
DFI | Director of Finance/CFO | 54 | 23-10-17 |
Reaz Rasul
CTO | Chief Tech/Sci/R&D Officer | - | 16-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Stephen Oesterle
BRD | Director/Board Member | 73 | 17-02-05 |
Peter Wilver
BRD | Director/Board Member | 64 | 22-05-09 |
| Director/Board Member | 64 | 19-02-17 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 13.07% | 254 M€ | +10.74% | - | |
| 1.87% | 9 M€ | 0.00% | ||
| 1.23% | 17 M€ | +7.73% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-16 | 35.17 | -0.73% | 5,884,003 |
| 24-05-15 | 35.43 | +0.54% | 4,907,021 |
| 24-05-14 | 35.24 | -0.54% | 4,472,962 |
| 24-05-13 | 35.43 | -0.73% | 4,461,722 |
| 24-05-10 | 35.69 | -0.72% | 3,962,996 |
Delayed Quote Nyse, May 16, 2024 at 04:00 pm EDT
More quotes
Baxter International Inc. specializes in the development, manufacturing and marketing of medical devices and medications intended for healthcare professionals. Net sales break down by family of products as follows:
- medicines and medical devices (33.8%): products intended for treating hemophilia (substitution clotting factors) and immune deficiencies (multi-purpose immunoglobins), and used in intensive care (human albumin) and biosurgery (fibrin adhesive, surgical gel, bone substitutes, hemostatic compresses, etc.);
- kidney dialysis drugs and equipment (30.1%);
- systems for delivering medications and intravenous therapy (15.2%): used in the fields of anesthesia, oncology (chemotherapy and radiation), parenteral nutrition, etc.;
- other (20.1%).
Export accounts for 52.7% of net sales.
Calendar
2024-07-24
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
35.17
USD
Average target price
46.47
USD
Spread / Average Target
+32.12%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -9.03% | 17.92B | |
| -4.72% | 182B | |
| +3.96% | 114B | |
| -2.93% | 68.38B | |
| +6.30% | 52.46B | |
| +8.02% | 44.25B | |
| +7.52% | 43.55B | |
| +26.18% | 32.69B | |
| +17.85% | 26.73B | |
| +0.57% | 25.79B |
- Stock Market
- Equities
- BAX Stock
